89 citations
,
March 2001 in “Endocrine practice” This article provides diagnosis and treatment guidelines for hyperandrogenic disorders in women but reports no new clinical results; it offers a summary of accepted scientific information and suggestions for clinical practice.
57 citations
,
January 1995 in “The American journal of medicine” This study discusses the use of oral contraceptives as a treatment for hyperandrogenism, showing improvement in hirsutism and acne for many women and possibly providing metabolic benefits with certain formulations.
22 citations
,
January 2002 in “Treatments in endocrinology” This review examines the role of androgens in cutaneous disorders and the potential therapeutic effects of different oral contraceptives, noting variations in individual responses and the influence of genetic and local factors but reports no new clinical results.
December 2024 in “Pharmaceutics” This review systematically examined recent advancements in spironolactone-loaded nanocarriers, revealing that lipid and vesicular nanoparticles enhance bioavailability and skin penetration for treating androgen-dependent disorders, but highlighted the need for further clinical studies to optimize their use.
352 citations
,
January 2006 in “The Journal of Clinical Endocrinology and Metabolism” This study reported that classic anovulatory PCOS was the most common androgen excess disorder, followed by mild ovulatory PCOS and idiopathic hyperandrogenism, among patients evaluated for clinical hyperandrogenism.
